Analysts have been eager to weigh in on the Healthcare sector with new ratings on Horizon Pharma Inc (HZNP) and Radius Health (RDUS).
Horizon Pharma Inc (HZNP)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Horizon Pharma Inc today and set a price target of $32. The company’s shares opened today at $26.72, close to its 52-week high of $29.44.
Chen commented:
“. Post a 1Q19 beat, we are reiterating our OW rating and 12- month PT of $32. We continue to expect upside to FactSet estimates for HZNP’s orphan as well as rheumatology businesses and multiple expansion to drive the stock higher.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 6.6% and a 38.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.
Currently, the analyst consensus on Horizon Pharma Inc is a Strong Buy with an average price target of $32.22, implying a 20.6% upside from current levels. In a report issued on May 1, Citigroup also upgraded the stock to Buy with a $32 price target.
See today’s analyst top recommended stocks >>
Radius Health (RDUS)
In a report released today, Chris Shibutani from Cowen & Co. maintained a Hold rating on Radius Health. The company’s shares opened today at $20.50.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.5% and a 42.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Radius Health with a $22 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
